Now, it’s worth noting Stock Advisor’s total average return is 973 % — a market-crushing outperformance compared to 195% for ...

What Happened? Shares of medical technology company Stryker (NYSE:SYK) jumped 4.1% in the afternoon session after analyst firm Raymond James upgraded the stock to "Outperform" from "Market Perform" ...

Stryker offers above-average revenue growth, robust margin leverage, and a compelling valuation relative to med-tech peers ...

Stryker SYK is well-poised for growth, backed by a robust robotic arm-assisted surgery platform, Mako, and a diversified product portfolio. An improvement in price also buoys optimism. Shares of this ...

Stryker builds an ASC ecosystem that drives growth, but margin pressure persists. Click here to read my latest analysis of ...

Raymond James cut Zimmer Biomet Holdings Inc (NYSE: ZBH) citing frustration with uneven growth. While the stock looks inexpensive and the long-term setup remains intact, the firm said inconsistent ...

Stryker (NYSE: SYK) has outperformed the market over the past 10 years by 1.46% on an annualized basis producing an average annual return of 14.57%. Currently, Stryker has a market capitalization of ...

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Stryker on January 7 and set a price target of $435.00. The company’s shares closed yesterday at $367.75.

Both companies are high-quality MedTech leaders, but their upside profiles diverge. Stryker’s diversification, consistent ...

Stryker (NYSE: SYK), the medical devices powerhouse, has recently launched its Sync Badge—a hands-free, wearable communication device designed to enhance collaboration among healthcare teams. This new ...